<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Biosciences</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A272DBEA-0D1F-4203-B758-69698FC352F1"><gtr:id>A272DBEA-0D1F-4203-B758-69698FC352F1</gtr:id><gtr:firstName>Siddharthan</gtr:firstName><gtr:surname>Chandran</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7759DE67-0824-4FA6-A9F0-A90442EB5E3B"><gtr:id>7759DE67-0824-4FA6-A9F0-A90442EB5E3B</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Allen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/53E7EF11-FCED-4F39-89E8-38E69990FC29"><gtr:id>53E7EF11-FCED-4F39-89E8-38E69990FC29</gtr:id><gtr:firstName>Anne Elizabeth</gtr:firstName><gtr:surname>Rosser</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0300331"><gtr:id>DB49A5EA-A23E-4E0C-8DE1-1F2B2258C361</gtr:id><gtr:title>Directed differentiation of human embryonic stem cells to forebrain neural progenitors</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300331</gtr:grantReference><gtr:abstractText>Embryonic stem cells, or ES cells, have the remarkable ability to differentiate into all cell types of the body. Controlled growth and differentiation of ES cells in the lab can be directed to generate large populations of specific types of cell. The advent of ES cells derived from human embryos has raised the exciting possibility that tissues required for human transplantation therapies could be grown in the lab, and circumvent the requirement for donor cells that are otherwise very difficult to source. This is particularly true neural transplantation that is currently being pioneered to treat disorders such as Parkinson?s and Huntington?s (HD) diseases, but is currently dependent on rare tissue, derived from elective aborted fetuses. One problem is that specific brain regions are characterized by the presence of different types of neuron, therefore to treat different disorders the right kind of neuron must first be generated. In this proposal we aim to control the differentiation of human ES cells to acquire the characteristic of the striatum, the region of the brain worst affected in HD, and the target for cell transplantation therapy. We will then test whether the derived cells will integrate and develop alongside host striatal tissue in animal models of HD.</gtr:abstractText><gtr:technicalSummary>Human embryonic stem cells (hESC) have enormous potential to provide a reproducible and stable supply of cells for neural transplantation therapies that would otherwise not be possible due to a lack of primary donor fetal tissue. This is particularly so for treatment of neurological disorders such as Huntington?s disease (HD). Here we propose to extend our previous studies on the directed neural differentiation of mouse embryonic stem cells to hESCs, with the specific purpose of generating neural progenitor cells characteristic of the developing striatum, and testing their functional development using established transplantation paradigms in the rat. The work will involve the application of developmental principles of neural patterning and lineage restriction to pluripotent hESCs, drawing significantly from extensive knowledge of the mechanisms of brain development in the mouse and other model vertebrate organisms. This proposal addresses issues central to the purpose of the Stem cell strategic grants call; (i) the development of defined medium for directed stem cell differentiation (ii) the development and definition of progenitor cell type specific markers (iii) comparison of ES cell line differentiation characteristics (vi) development of protocols of significance to human therapy.</gtr:technicalSummary><gtr:fund><gtr:end>2009-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>321908</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Institute for Stem cell Therapy and Exploration of Monogenic diseases (I-Stem)</gtr:department><gtr:description>STEM-HD</gtr:description><gtr:id>D9E4C765-BFED-4422-8BF2-CFE311A03FA0</gtr:id><gtr:impact>The project has established proof of concept for utilising disease carrying human embryonic stem cells derived from preimplantation diagnosed embryos for in vitro disease modelling. A platform for highthroughput drug screening using the human cells has been developed, and novel disease biomarkers have been identified. Publications 17095704 Other manuscripts in preparation</gtr:impact><gtr:outcomeId>6D56E2EC6ED-1</gtr:outcomeId><gtr:partnerContribution>Exchange of information and materials</gtr:partnerContribution><gtr:piContribution>EU FP6 funded STREP. Stem cells for therapeutics and exploration of mechanisms in Huntingtons disease. Workpackage 1 leader: directed neural differentiation of human ES cells, to further develop differentiation protocols, particulalry for applications in high throughput screening. Gene expression profiling and analysis of wt and HD hESs and neural derivatives Physiological analysis of hES derived neurons</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>iPS technology</gtr:description><gtr:id>E63208FC-B923-443E-9C28-A231A2EA3C5C</gtr:id><gtr:impact>We obtained supplementry funding to this award to develop iPS technology. This has now been established locally and is integral to future planned research programmes.</gtr:impact><gtr:outcomeId>6FF0B1FF534-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have provided valuable expertise and reagents for lentiviral generation and neurodegenerative disease mechanisms</gtr:partnerContribution><gtr:piContribution>We have provided expertise in human ES cell culture, differentiation, and disease modelling</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Laboratory open day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>20343CE8-EEAB-4892-86C1-335366B4EC0B</gtr:id><gtr:impact>Together with the Brain Repair Group at Cardiff University we hold open days for HD and PD patient and support groups to inform them of ongoing research related to stem cells and brain repair

Direct communication with patient groups provides important support and hope.</gtr:impact><gtr:outcomeId>15AB7EB5FB0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public debate - Cardiff</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D2701967-2872-478D-AF92-A65749DE2E86</gtr:id><gtr:impact>Public debate on stem cell medicine and ethics. Hosted by Techniquest Cardiff

Education of public on realistic issues and potentials of stem cell research</gtr:impact><gtr:outcomeId>FD75CEBCA67</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7174857F-84E8-4872-8D1C-EFC2E2D03509</gtr:id><gtr:outcomeId>79F52903AF70</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Development of chemically defined (to be GMP compliant) culture media and protocols for directed neural differentiation. Media avoid use of all animal products, and are used for efficient generationa nd expansion of neural progenitors.</gtr:description><gtr:id>A510DC3F-F115-45E9-A9D7-EAE28BBDD716</gtr:id><gtr:impact>The basic protocol is being further adapted to establish GMP compliant conditions to derive cells for neural transplantation therapies</gtr:impact><gtr:outcomeId>FD9851C5D3A</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Human ES cell neural differentiation methodology</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Differentiation protocols developed have been applied to ES cell derived from Huntington's Disease embryos do derive neurons for in vitro disease modelling of HD and development of cells for assay development and drug screens</gtr:description><gtr:id>74CB6389-808C-4F1C-8577-E0C8FA424825</gtr:id><gtr:impact>The research formed a basis for studies in the STEM-HD FP6 programme to develop human ES to model and study HD</gtr:impact><gtr:outcomeId>E9D7EE41A01</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Neural disease modelling using human ES cells</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Bicistronic lentiviral vectors were made for iPS cell generation. Oct4-IRES-Sox2 and Klf4-IRES-Nanog constructs were made in integrating and non-integrating virus</gtr:description><gtr:id>AE76FA74-2162-4599-BEDB-86007DDA6023</gtr:id><gtr:impact>Vectors have been used to derive human iPS cells. Establishing the technology within the group will allow us to further develop human models of neurodegenerative disease.</gtr:impact><gtr:outcomeId>36D51EB3739</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Bicistronic Lentiviral iPS vectors</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7F30DE99-7764-4FDB-A491-347C4ECEBAE9</gtr:id><gtr:title>Telomere length maintenance in stem cell populations.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f894059129ba550494ed423aba9e96bf"><gtr:id>f894059129ba550494ed423aba9e96bf</gtr:id><gtr:otherNames>Allen ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>7E5928E6648</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12A12EB8-8782-4933-96A8-16A59E9D5F47</gtr:id><gtr:title>Neonatal desensitization allows long-term survival of neural xenotransplants without immunosuppression.</gtr:title><gtr:parentPublicationTitle>Nature methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9dd96bb733c0726221ef84de4144119"><gtr:id>f9dd96bb733c0726221ef84de4144119</gtr:id><gtr:otherNames>Kelly CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1548-7091</gtr:issn><gtr:outcomeId>5972FA4212F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7068714-74FE-4C96-8940-5B07C1841891</gtr:id><gtr:title>Temporal and epigenetic regulation of neurodevelopmental plasticity.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f894059129ba550494ed423aba9e96bf"><gtr:id>f894059129ba550494ed423aba9e96bf</gtr:id><gtr:otherNames>Allen ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>F0ABCB6FD12</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46BBDEC1-0D4A-4BF9-8E15-7C16CA25FEB5</gtr:id><gtr:title>Environmental signals regulate lineage choice and temporal maturation of neural stem cells from human embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fb120c58a3a06207c156f6b551ad790"><gtr:id>9fb120c58a3a06207c156f6b551ad790</gtr:id><gtr:otherNames>Joannides AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5F9E1B0D144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3886F7E-7D97-4C99-9201-8E5ADB50DCB7</gtr:id><gtr:title>A scaleable and defined system for generating neural stem cells from human embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fb120c58a3a06207c156f6b551ad790"><gtr:id>9fb120c58a3a06207c156f6b551ad790</gtr:id><gtr:otherNames>Joannides AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>1D847642F5F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FB42426-C434-4413-A5EF-E84780CC1E46</gtr:id><gtr:title>Embryonic stem cell-derived neural progenitors display temporal restriction to neural patterning.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bbe9fa15077f92a8ad0f79b18005065"><gtr:id>3bbe9fa15077f92a8ad0f79b18005065</gtr:id><gtr:otherNames>Bouhon IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>F09B7B8CA5E</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300331</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>